179 related articles for article (PubMed ID: 32449878)
1. Enabling speed to clinic for monoclonal antibody programs using a pool of clones for IND-enabling toxicity studies.
Bolisetty P; Tremml G; Xu S; Khetan A
MAbs; 2020; 12(1):1763727. PubMed ID: 32449878
[TBL] [Abstract][Full Text] [Related]
2. A strategy to accelerate protein production from a pool of clones in Chinese hamster ovary cells for toxicology studies.
Hu Z; Hsu W; Pynn A; Ng D; Quicho D; Adem Y; Kwong Z; Mauger B; Joly J; Snedecor B; Laird MW; Andersen DC; Shen A
Biotechnol Prog; 2017 Nov; 33(6):1449-1455. PubMed ID: 28371489
[TBL] [Abstract][Full Text] [Related]
3. Leveraging a CHO cell line toolkit to accelerate biotherapeutics into the clinic.
Wright C; Alves C; Kshirsagar R; Pieracci J; Estes S
Biotechnol Prog; 2017 Nov; 33(6):1468-1475. PubMed ID: 28842948
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of therapeutic antibody candidates derived from mini-pool and clonal cell lines.
Fan L; Rizzi G; Bierilo K; Tian J; Yee JC; Russell R; Das TK
Biotechnol Prog; 2017 Nov; 33(6):1456-1462. PubMed ID: 28393481
[TBL] [Abstract][Full Text] [Related]
5. Strategic deployment of CHO expression platforms to deliver Pfizer's Monoclonal Antibody Portfolio.
Scarcelli JJ; Shang TQ; Iskra T; Allen MJ; Zhang L
Biotechnol Prog; 2017 Nov; 33(6):1463-1467. PubMed ID: 28480558
[TBL] [Abstract][Full Text] [Related]
6. Accelerating patient access to novel biologics using stable pool-derived product for non-clinical studies and single clone-derived product for clinical studies.
Munro TP; Le K; Le H; Zhang L; Stevens J; Soice N; Benchaar SA; Hong RW; Goudar CT
Biotechnol Prog; 2017 Nov; 33(6):1476-1482. PubMed ID: 29055113
[TBL] [Abstract][Full Text] [Related]
7. Utilizing targeted integration CHO pools to potentially accelerate the GMP manufacturing of monoclonal and bispecific antibodies.
Barnard GC; Zhou M; Shen A; Yuk IH; Laird MW
Biotechnol Prog; 2024; 40(1):e3399. PubMed ID: 37874920
[TBL] [Abstract][Full Text] [Related]
8. Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable pool.
Schmieder V; Fieder J; Drerup R; Gutierrez EA; Guelch C; Stolzenberger J; Stumbaum M; Mueller VS; Higel F; Bergbauer M; Bornhoefft K; Wittner M; Gronemeyer P; Braig C; Huber M; Reisenauer-Schaupp A; Mueller MM; Schuette M; Puengel S; Lindner B; Schmidt M; Schulz P; Fischer S
J Biotechnol; 2022 Apr; 349():53-64. PubMed ID: 35341894
[TBL] [Abstract][Full Text] [Related]
9. A CHO stable pool production platform for rapid clinical development of trimeric SARS-CoV-2 spike subunit vaccine antigens.
Joubert S; Stuible M; Lord-Dufour S; Lamoureux L; Vaillancourt F; Perret S; Ouimet M; Pelletier A; Bisson L; Mahimkar R; Pham PL; L Ecuyer-Coelho H; Roy M; Voyer R; Baardsnes J; Sauvageau J; St-Michael F; Robotham A; Kelly J; Acel A; Schrag JD; El Bakkouri M; Durocher Y
Biotechnol Bioeng; 2023 Jul; 120(7):1746-1761. PubMed ID: 36987713
[TBL] [Abstract][Full Text] [Related]
10. The Augmenting Effects of the tDNA Insulator on Stable Expression of Monoclonal Antibody in Chinese Hamster Ovary Cells.
Naderi F; Hashemi M; Bayat H; Mohammadian O; Pourmaleki E; Etemadzadeh MH; Rahimpour A
Monoclon Antib Immunodiagn Immunother; 2018 Nov; 37(5):200-206. PubMed ID: 30362930
[TBL] [Abstract][Full Text] [Related]
11. Optimization of cell line development in the GS-CHO expression system using a high-throughput, single cell-based clone selection system.
Nakamura T; Omasa T
J Biosci Bioeng; 2015 Sep; 120(3):323-9. PubMed ID: 25792187
[TBL] [Abstract][Full Text] [Related]
12. Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells.
Xu G; Yu C; Wang W; Fu C; Liu H; Zhu Y; Li Y; Liu C; Fu Z; Wu G; Li M; Guo S; Yu X; Du J; Yang Y; Duan M; Cui Y; Feng H; Wang L
MAbs; 2022; 14(1):2005507. PubMed ID: 34923915
[TBL] [Abstract][Full Text] [Related]
13. Reducing recombinant protein expression during CHO pool selection enhances frequency of high-producing cells.
Poulain A; Mullick A; Massie B; Durocher Y
J Biotechnol; 2019 Apr; 296():32-41. PubMed ID: 30885656
[TBL] [Abstract][Full Text] [Related]
14. The use of site-specific recombination and cassette exchange technologies for monoclonal antibody production in Chinese Hamster ovary cells: retrospective analysis and future directions.
Srirangan K; Loignon M; Durocher Y
Crit Rev Biotechnol; 2020 Sep; 40(6):833-851. PubMed ID: 32456474
[TBL] [Abstract][Full Text] [Related]
15. Lengthening of high-yield production levels of monoclonal antibody-producing Chinese hamster ovary cells by downregulation of breast cancer 1.
Matsuyama R; Yamano N; Kawamura N; Omasa T
J Biosci Bioeng; 2017 Mar; 123(3):382-389. PubMed ID: 27742176
[TBL] [Abstract][Full Text] [Related]
16. Early prediction of instability of Chinese hamster ovary cell lines expressing recombinant antibodies and antibody-fusion proteins.
Dorai H; Corisdeo S; Ellis D; Kinney C; Chomo M; Hawley-Nelson P; Moore G; Betenbaugh MJ; Ganguly S
Biotechnol Bioeng; 2012 Apr; 109(4):1016-30. PubMed ID: 22068683
[TBL] [Abstract][Full Text] [Related]
17. A hybrid approach identifies metabolic signatures of high-producers for chinese hamster ovary clone selection and process optimization.
Popp O; Müller D; Didzus K; Paul W; Lipsmeier F; Kirchner F; Niklas J; Mauch K; Beaucamp N
Biotechnol Bioeng; 2016 Sep; 113(9):2005-19. PubMed ID: 26913695
[TBL] [Abstract][Full Text] [Related]
18. Deletion of a telomeric region on chromosome 8 correlates with higher productivity and stability of CHO cell lines.
Ritter A; Voedisch B; Wienberg J; Wilms B; Geisse S; Jostock T; Laux H
Biotechnol Bioeng; 2016 May; 113(5):1084-93. PubMed ID: 26523402
[TBL] [Abstract][Full Text] [Related]
19. A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential.
Luchese MD; Lopes Dos Santos M; Garbuio A; Targino RC; Mansueli CP; Tsuruta LR; Quintilio W; Moro AM
Immunol Res; 2018 Jun; 66(3):392-405. PubMed ID: 29855993
[TBL] [Abstract][Full Text] [Related]
20. Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells.
Fan L; Kadura I; Krebs LE; Hatfield CC; Shaw MM; Frye CC
Biotechnol Bioeng; 2012 Apr; 109(4):1007-15. PubMed ID: 22068567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
